Last updated: February 15, 2026
Overview of the Product
NDC 00642-7470 is marketed as Zepzelca (lurbinectedin), which was approved by the U.S. FDA in June 2020 for metastatic small cell lung cancer (SCLC) with disease progression following platinum-based chemotherapy.[1] It is an oncology drug developed by Pharma Mar (Zepzelca's manufacturer), targeting a niche with limited treatment options.
Market Landscape
Indication and Patient Population
Lurbinectedin addresses a small but significant segment within the oncology market. SCLC accounts for approximately 15% of all lung cancers, with a median survival of 10-12 months once metastatic.[2] The FDA approval expands treatment options for relapsed SCLC, particularly in patients with disease progression post-chemotherapy.
Competitive Position
The primary competitors include:
- Topotecan (Hycamptin): Approved since 1997 for relapsed SCLC.
- Lurbinectedin's differentiation lies in its novel mechanism of action—targeting oncogenic transcription and DNA binding—potentially offering better efficacy or tolerability. However, clinical data is limited; Phase III trials are ongoing.
Market Penetration
Initial sales are modest, given the drug's recent market entry and the small population size. Pharma Mar's strategy involves focusing on key centers specializing in lung cancer.
Pricing and Reimbursement
Current Pricing
- List price: Approximately $11,055 per vial.[3]
- Dosage regimens imply total treatment costs ranging from $30,000 to $50,000 per patient, depending on treatment duration and dosing cycle.
Reimbursement Landscape
- Reimbursement hinges on approval by CMS for Medicare and private payers.
- As an orphan drug, Zepzelca benefits from incentives that may expedite coverage decisions.
Pricing Trends
The price aligns with other oncology niche drugs, typically in the $10,000-$15,000 range per vial. The relatively high price reflects the targeted indication and R&D costs.
Price Projections
Short-term (Next 1-2 years)
- Stabilization of current pricing, barring market entry of competing treatments or significant data on efficacy.
- Price discounts unlikely unless competitive pressures or reimbursement issues arise.
- Sales expected to remain low, estimated at $50-$100 million annually, driven by limited patient access.
Medium-term (3-5 years)
- Potential price adjustments in response to increased competition or patent challenges.
- If Phase III trials demonstrate superior efficacy, upward pricing pressure could emerge.
- Broader adoption may increase revenues; projected sales could reach $150-$200 million annually.
Long-term (Beyond 5 years)
- Price may declineIf biosimilar or generic competitors emerge, or if manufacturing costs decrease.
- Alternatively, successful expansion into other indications could sustain higher prices over time.
Market Growth Drivers
- Expand indications to first-line or maintenance settings.
- Broaden geographic approval beyond the U.S.
- Demonstrate compelling overall survival benefits through ongoing clinical trials.
Regulatory and Policy Factors
- FDA's accelerated approval pathway led to early market entry.
- Reimbursement policies influenced by cost-effectiveness evaluations will affect revenue.
- Potential combination therapies could expand usage and thus impact pricing strategies.
Comparative Price Analysis
| Drug |
Approved Indication |
Launch Price per Vial |
Market Segment |
| Zepzelca (00642-7470) |
Relapsed SCLC, post-chemotherapy |
$11,055 |
Niche, oncology, small patient population |
| Topotecan |
Relapsed SCLC |
~$1,800 per vial |
Established, less targeted |
| Lurbinectedin (2020) |
Same as Zepzelca, same manufacturer |
Same as above |
Same product, different markets |
Summary
The drug's price is consistent with niche oncology therapies, targeting a small, high-cost market. Sales are projected to grow modestly with clinical success and expanded indications, but the high cost limits widespread adoption. Competitor entry or further clinical data could influence future prices.
Key Takeaways
- NDC 00642-7470, marketed as Zepzelca, is a targeted therapy for relapsed SCLC, with a list price of about $11,000 per vial.
- The market remains small but potentially growing, contingent on clinical trial results and approval expansion.
- Short-term sales are expected to stay in the $50-100 million range; growth potential exists if additional indications or approval in other regions occur.
- Price stability is likely unless competitive dynamics or reimbursement pressures change.
- Long-term pricing may decline if biosimilars or generics enter the market, but successful expansion could sustain higher prices.
FAQs
1. What factors most significantly influence the price of Zepzelca?
Clinical efficacy, competing therapies, reimbursement policies, and manufacturing costs primarily impact the pricing of Zepzelca.
2. How does the price of Zepzelca compare to other oncology drugs?
Zepzelca's price per vial is higher than traditional chemotherapies like topotecan but aligns with niche, targeted oncology agents.
3. Are there any planned changes to the pricing or approvals for this drug?
No announced changes; future pricing adjustments depend on clinical trial outcomes and regulatory decisions.
4. What is the potential for market expansion?
Expanding indications to first-line treatment or other cancers, along with geographic approval, could significantly increase sales volume.
5. How do reimbursement policies affect the drug's market penetration?
Reimbursement challenges or delays could restrict access and sales despite high pricing.
References
- U.S. Food and Drug Administration. Zepzelca (lurbinectedin) approval announcement. June 2020.
- American Cancer Society. Small Cell Lung Cancer Facts & Figures. 2022.
- Redbook Price Verification. Price per vial. 2023.
